Wibke Stansen

Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial

Carlo Vancheri, Michael Kreuter, Luca Richeldi et al. · American Journal of Respiratory and Critical Care Medicine · 2017 · 297 citations

Medicine, Pharmacology, Pharmacotherapy +13

Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON

Bruno Crestani, John T. Huggins, Mitchell Kaye et al. · The Lancet Respiratory Medicine · 2018 · 239 citations

Medicine, Clinical Sciences, Internal Medicine +6

First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value

Wim Wuyts, Martin Kolb, Susanne Stowasser et al. · Lung · 2016 · 120 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +14

Retrospective Case—Control Study of the Effects of Long-Term Dosing with Meloxicam on Renal Function in Aged Cats with Degenerative Joint Disease

Richard A Gowan, Amy E Lingard, Laura Johnston et al. · Journal of Feline Medicine and Surgery · 2011 · 109 citations · Full text

Medicine, Nephrology, Veterinary Pharmacology +16

Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis

S. Jouneau, Bruno Crestani, Ronan Thibault et al. · Respiratory Research · 2020 · 79 citations · Full text

Medicine, Internal Medicine, Functional Decline +16